Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSI Seeks Partner For DPP-4 Inhibitor Paused At Phase III Gate

This article was originally published in The Pink Sheet Daily

Executive Summary

OSI’s metabolic business unit Prosidion also aims to out-license its glucokinase activator candidate in the next three months, Prosidion president tells “The Pink Sheet” DAILY.

You may also be interested in...



Astellas Considers Options To Shed All Or Parts Of Diabetes Unit Prosidion

TOKYO - Astellas is weighing its options for metabolic subsidiary Prosidion, likely divesting all or part of it, as the company continues its integration, and shedding, of OSI Pharmaceuticals. If it sells off Prosidion, Astellas will be left with few pipeline entries in the diabetes space

OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Goddard talks about OSI’s metabolic syndrome pipeline, competing with Merck in the DPP-4 space and profitability.

OSI Pharmaceuticals President Colin Goddard: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Goddard talks about OSI’s metabolic syndrome pipeline, competing with Merck in the DPP-4 space and profitability.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135495

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel